⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91319 | 0.96 | — | — | |
| SCHEMBL17970603 | 0.87 | — | — | |
| SCHEMBL8590083 | 0.87 | — | — | |
| SCHEMBL16409171 | 0.72 | — | — | |
| SCHEMBL6901576 | 0.67 | — | — | |
| SCHEMBL12548979 | 0.67 | — | — | |
| SCHEMBL25438483 | 0.65 | — | — | |
| SCHEMBL25973681 | 0.65 | — | — | |
| SCHEMBL29282995 | 0.65 | — | — | |
| Methyl Alcohol SCHEMBL29281330 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239778-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2024148149-A2 | COMPOSITIONS AND METHODS FOR CONTROLLING GLUCOSE LEVELS | SIRTSEI PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-11993593-B2 | Griseofulvin compound and pharmaceutical use thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | C4 THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4347044-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024059705-A1 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION IN FEMALES | SIRTSEI PHARMACEUTICALS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| WO-2024026443-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MEMORY AND COGNITION | SIRTSEI PHARMACEUTICALS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230136792-A1 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND PREMATURE AGING DISORDERS | SIRTSEI PHARMACEUTICALS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2019000236-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-2670752-B1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-03-16 | — | — | EP | disclosed |
| CN-103827110-A | N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors | HOFFMANN LA ROCHE | 2014-05-28 | — | — | CN | disclosed |
| US-20100203445-A1 | NEGATIVE RESIST COMPOSITION AND RESIST PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20080206668-A1 | NEGATIVE RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080206668-A1 | NEGATIVE RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-08-28 | — | — | US | disclosed |
| US-6444616-B1 | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-03 | — | — | US | disclosed |
| US-6130225-A | Substituted p-trifluoromethylphenyluracils | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-10 | — | — | US | disclosed |
| EP-0923562-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AG (DE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998006706-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | disclosed |